Neuronetics Inc Revenue Growth Rates (STIM), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Neuronetics Inc   (NASDAQ: STIM)
 

STIM's Revenue Growth by Quarter and Year

Neuronetics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/STIM/growth
https://api.csimarket.com/api/v1/companies/STIM/fundamentals
https://api.csimarket.com/api/v1/companies/STIM/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
STIM Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 42.06
2nd Quarter June 41.63
1st Quarter March 34.15
FY 117.84

STIMs Annual Revenue
Neuronetics Inc 's Revenue in the fiscal year 2025 $ 148.31 millions
Neuronetics Inc 's Revenue in the fiscal year 2024 $ 74.16 millions
Neuronetics Inc 's Revenue in the fiscal year 2023 $ 70.71 millions
Neuronetics Inc 's Revenue in the fiscal year 2022 $ 65.21 millions
Neuronetics Inc 's Revenue in the fiscal year 2021 $ 55.31 millions




STIM Revenue third quarter 2026 Y/Y Growth Comment
Neuronetics Inc achieved in the third quarter 2026, above Company average Revenue increase of 13.34% year on year, to $ 42.06 millions.

Looking into third quarter 2026 results within Medical Equipment & Supplies industry 23 other companies have achieved higher Revenue growth. While Neuronetics Inc ' s Revenue growth of 13.34% ranks overall at the positon no. 480 in the third quarter 2026.


STIM Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 13.34 %
2nd Quarter June 10.25 %
1st Quarter March 7.59 %
FY   -

Financial Statements
Neuronetics Inc 's third quarter 2026 Revenue $ 42.06 millions STIM's Income Statement
Neuronetics Inc 's third quarter 2025 Revenue $ 37.11 millions Quarterly STIM's Income Statement


STIM Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 1.04 %
2nd Quarter June 21.9 %
1st Quarter March -18.11 %
FY (Year on Year)   -


Back to STIM Growth rate Comparisons >> Back to STIM Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #24
Healthcare Sector #97
Overall #480

Revenue Y/Y Growth Statistics
High Average Low
38.64 % 6.25 % -33.88 %
(Mar 31 2025)   (Mar 31 2020)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #24
Healthcare Sector #97
Overall #480
Revenue Y/Y Growth Statistics
High Average Low
38.64 % 6.25 % -33.88 %
(Mar 31 2025)   (Mar 31 2020)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Neuronetics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
38.64 % 6.25 % -33.88 %
(Mar 31 2025)  


STIM's III. Quarter Q/Q Revenue Comment
Neuronetics Inc achieved in the III. Quarter 2026 below company average Revenue growth of 1.04% quarter on quarter, to $ 42.06 millions.

Although the III. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the -1.72% growth in the III. Quarter a year ago

Within Medical Equipment & Supplies industry 23 other companies have achieved higher Revenue quarter on quarter growth. While Neuronetics Inc 's Revenue growth quarter on quarter, overall rank is 486.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #24
Healthcare Sector #98
Overall #486
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #24
Healthcare Sector #98
Overall #486
Revenue Q/Q Growth Statistics
High Average Low
38.64 % 6.25 % -33.88 %
(Mar 31 2025)  


STIM's III. Quarter Q/Q Revenue Comment
Neuronetics Inc achieved in the III. Quarter 2026 below company average Revenue growth of 1.04% quarter on quarter, to $ 42.06 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -1.72% in the III. Quarter a year ago.

Within Medical Equipment & Supplies industry 23 other companies have achieved higher Revenue quarter on quarter growth. While Neuronetics Inc 's Revenue growth quarter on quarter, overall rank is 486.


Neuronetics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 154.59
Y / Y Revenue Growth (TTM) 40.04 %
Year on Year Revenue Growth Overall Ranking # 734
Seqeuential Revenue Change (TTM) 2.57 %
Seq. Revenue Growth (TTM) Overall Ranking # 700


Cumulative Revenue growth Comment
Assuming the Neuronetics Inc 's fiscal year would have ended in Jun 30 2026, Neuronetics Inc would have reprted above average annual Revenue growth of 40.04% year on year, of $ 155 millions.
This marks a slow-down of the companys growth trends and from the 69.71% increase in Mar 31 2026.

In the Healthcare sector 153 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 620 to 734.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 43
Healthcare Sector # 154
Overall # 734

Revenue TTM Y/Y Growth Statistics
High Average Low
99.98 %
 18.21 %
-21.41 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 43
Sector # 145
S&P 500 # 700
Cumulative Revenue growth Comment
Assuming the Neuronetics Inc 's fiscal year would have ended in Jun 30 2026, Neuronetics Inc would have reprted above average annual Revenue growth of 40.04% year on year, of $ 155 millions.
This marks a slow-down of the companys growth trends and from the 69.71% increase in Mar 31 2026.

In the Healthcare sector 153 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 620 to 734.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 43
Healthcare Sector # 154
Overall # 734

Revenue TTM Y/Y Growth Statistics
High Average Low
99.98 %
18.21 %
-21.41 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 43
Sector # 145
S&P 500 # 700




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
STIM's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Prestige Consumer Healthcare Inc 22.93%$ 22.929 millions
Acadia Pharmaceuticals Inc 22.85%$ 22.847 millions
Veracyte Inc 22.10%$ 22.105 millions
Alkermes Plc 21.80%$ 21.804 millions
Alpha Teknova Inc 21.52%$ 21.523 millions
Orthopediatrics Corp20.55%$ 20.551 millions
Insulet Corporation19.21%$ 19.213 millions
Schrodinger Inc 18.72%$ 18.715 millions
Procept Biorobotics Corporation18.41%$ 18.414 millions
Supernus Pharmaceuticals inc 18.05%$ 18.047 millions
Outset Medical Inc 17.51%$ 17.510 millions
Alnylam Pharmaceuticals Inc 16.74%$ 16.738 millions
Rigel Pharmaceuticals Inc16.45%$ 16.452 millions
Si bone inc 16.42%$ 16.424 millions
Ars Pharmaceuticals Inc 16.03%$ 16.027 millions
Atricure Inc 15.84%$ 15.839 millions
Ardelyx inc 15.70%$ 15.704 millions
Novocure Limited15.67%$ 15.666 millions
Penumbra Inc15.64%$ 15.636 millions
Irhythm Holdings Inc 15.34%$ 15.339 millions
Msa Safety Inc14.72%$ 14.716 millions
Ensign Group Inc14.47%$ 14.471 millions
Abbott Laboratories14.46%$ 14.460 millions
Electrocore Inc 14.40%$ 14.404 millions
Allogene Therapeutics Inc 14.29%$ 14.286 millions
Tandem Diabetes Care Inc 14.26%$ 14.257 millions
Iradimed Corporation14.15%$ 14.154 millions
Apyx Medical Corp14.09%$ 14.093 millions
Incyte Corporation14.00%$ 13.999 millions
Aurinia Pharmaceuticals Inc 13.93%$ 13.926 millions


About Neuronetics Inc Revenue Growth Rates (STIM), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Neuronetics Inc (CIK 1227636).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-122380
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Neuronetics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.